Abstract: This disclosure provides methods and compositions for inhibiting immune responses. The disclosure also provides methods and compositions for inhibiting graft rejection and promoting or prolonging graft survival.
Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.
Type:
Grant
Filed:
October 14, 2015
Date of Patent:
April 25, 2017
Assignee:
Wyeth LLC
Inventors:
Annaliesa Sybil Anderson, Robert G. K. Donald, Kathrin Ute Jansen, Michael James Flint
Abstract: Particles of an organic acid salt of an amino acid amide or ester local anesthetic are employed as agents for the improved alleviation of pain. Particularly, the particles find use with surgically created wounds, where the particles may be administered directly into the bed of the wound or topically for transdermal transport.
Type:
Grant
Filed:
November 5, 2015
Date of Patent:
May 9, 2017
Assignee:
SVIP5 LLC
Inventors:
Samuel P. Sawan, Daniel Jacobs, Tadmor Shalon
Abstract: Described herein are compositions and methods for preventing and/or treating diseases involving aberrant angiogenesis employing one or more benzo[c]chromen-6-one derivatives.
Type:
Grant
Filed:
July 1, 2015
Date of Patent:
September 26, 2017
Assignee:
PALOMA PHARMACEUTICALS, INC.
Inventors:
David I. Sherris, Manjinder Gill, Fupeng Ma, Sanjivanjit Kaur Bhal, Robert Dunn-Dufault, Miklos Feher, Peter Redden, Jonathan Schmidt
Abstract: The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-?) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising said human protein tyrosine phosphatase beta (HPTP-?) inhibitors, and to methods for regulating angiogenesis.
Type:
Grant
Filed:
November 11, 2015
Date of Patent:
October 31, 2017
Assignee:
Aerpio Therapeutics, Inc.
Inventors:
Jeffrey Lyle Gray, Kande K. D. Amarasinghe, Cynthia Monesa Clark, Ryan Matthew Nichols, Matthew B. Maier
Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
Type:
Grant
Filed:
February 24, 2016
Date of Patent:
November 14, 2017
Assignee:
VANDA PHARMACEUTICALS, INC.
Inventors:
Marlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
Abstract: An isolated sucrose synthase peptide. Also, a method of preparing ADPglucose by incubating the isolated sucrose synthase peptide with ADP in suitable conditions and then isolating and purifying the ADPG produced. Also, an assay kit for the spectrophotometric, fluorimetric or amperometric determination of sucrose, which kit includes the isolated sucrose synthase peptide. Also, a method of producing a transgenic plant that overexpresses sucrose synthase by inserting a genetic construct containing a DNA fragment that encodes the sucrose synthase peptide into a vector and transferring to a plant genome, and a transgenic plant obtained thereby.
Type:
Grant
Filed:
May 1, 2014
Date of Patent:
December 19, 2017
Assignees:
UNIVERSIDAD PUBLICA DE NAVARRA, CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
Inventors:
Miren Edurne Baroja Fernandez, Francisco José Muñoz Perez, Francisco Javier Pozueta Romero, Maria Teresa Moran Zorzano, Nora Alonso Casajus
Abstract: Disclosed are methods and kits applicable to sequencing methods, such as Sanger dideoxy sequencing methods. The methods and kits disclosed utilize a cationically charged nucleic acid terminator in combination with a discriminatory polymerase.
Type:
Grant
Filed:
September 30, 2014
Date of Patent:
January 23, 2018
Assignee:
Applied Biosystems, LLC
Inventors:
Barnett Rosenblum, Steven Menchen, Shaheer Khan, Paul Kenney
Abstract: The invention refers to a composition comprising one or more tannase-producing strains of Lactobacillus having the ability to adhere to the human intestinal mucosa in combination with tannin. New tannase-producing strains of Lactobacillus plantarum are a.
Abstract: Disclosed are a stable recombinant cell clones which are stable in serum- and protein-free medium for at least 40 generations, a biomass obtained by multiplying the stable cell clone under serum- and protein-free culturing conditions, and a method of preparing recombinant proteins by means of the biomass. Furthermore, the invention relates to a method of recovering stable recombinant cell clones.
Type:
Grant
Filed:
December 11, 2014
Date of Patent:
March 6, 2018
Assignees:
Baxalta Incorporated, Baxalta GmbH
Inventors:
Manfred Reiter, Wolfgang Mundt, Friedrich Dorner
Abstract: The present invention relates to bioactive ingredients that include isolated bioactive fractions derived from cell juice of fresh biomass of a feverfew (Tanacetum parthenium) plant. The bioactive fractions are either free of or substantially free of ?-unsaturated ?-lactones (e.g., parthenolide). Further, the bioactive fractions have anti-inflammatory and antioxidant activity. The present invention also relates to a method for isolating a bioactive fraction that is derived from cell juice of fresh biomass of a feverfew (Tanacetum parthenium) plant and that is at least substantially free of ?-unsaturated ?-lactones (e.g., parthenolide). The present invention also relates to a method for preparing a stabilized cell juice serum fraction and a stabilized concentrated cell juice serum fraction that are free of ?-unsaturated ?-lactones (e.g., parthenolide).
Abstract: Disclosed are a stable recombinant cell clones which are stable in serum- and protein-free medium for at least 40 generations, a biomass obtained by multiplying the stable cell clone under serum- and protein-free culturing conditions, and a method of preparing recombinant proteins by means of the biomass. Furthermore, the invention relates to a method of recovering stable recombinant cell clones.
Type:
Grant
Filed:
July 6, 2016
Date of Patent:
May 22, 2018
Assignees:
Baxalta Incorporated, Baxalta GmbH
Inventors:
Manfred Reiter, Wolfgang Mundt, Friedrich Dorner
Abstract: Disclosed are a stable recombinant cell clones which are stable in serum- and protein-free medium for at least 40 generations, a biomass obtained by multiplying the stable cell clone under serum- and protein-free culturing conditions, and a method of preparing recombinant proteins by means of the biomass. Furthermore, the invention relates to a method of recovering stable recombinant cell clones.
Type:
Grant
Filed:
July 6, 2016
Date of Patent:
June 19, 2018
Assignees:
Baxalta Incorporated, Baxalta GmbH
Inventors:
Manfred Reiter, Wolfgang Mundt, Friedrich Dorner
Abstract: The present invention involves a new synthesis route for the formation of lactylates. The method comprises reacting a dilactide with a compound comprising a hydroxy group. This reaction is preferably carried out in the presence of a cation or other source of alkalinity. Preferred compounds comprising a hydroxy group include any fatty acid and fatty acid alcohol (particularly C1-C26 fatty acid chains). Preferred cations include cations of Group I and II metals, with sodium, calcium, and potassium cations being particularly preferred. The inventive reactions proceed much more rapidly than prior art lactylate synthesis reactions, and can be used to form 1-, 2-, 3-, 4-, and 5-lactylates.
Abstract: This invention is in the field of treating or preventing inflammation in humans and animals and relates to pharmaceutical compositions and methods for treating or preventing various inflammatory conditions. In particular, the invention relates to compositions and methods for treating or preventing inflammatory conditions such as citrulline-related inflammatory diseases. The invention provides specific binding molecules directed against citrulline-containing epitopes for use in the therapy and prevention of inflammatory conditions.
Type:
Grant
Filed:
March 3, 2017
Date of Patent:
August 14, 2018
Assignee:
MODIQUEST B.V.
Inventors:
Jozef Maria Hendrik Raats, Renato Gerardus Silvano Chirivi
Abstract: Embolic compositions comprising macromers having a backbone comprising a polymeric backbone comprising units with a 1,2-diol or 1,3-diol structure, such as polyvinyl alcohol, and pendant chains bearing crosslinkable groups and, optionally, other modifiers. When crosslinked, the macromers form hydrogels having many properties advantageous for use as embolic agents to block and fill lumens and spaces. The embolic compositions can be used as liquid embolic agents and crosslinked in situ or as preformed embolic articles, such as microspheres.
Type:
Grant
Filed:
July 17, 2014
Date of Patent:
November 13, 2018
Assignee:
BioCure, Inc.
Inventors:
Dennis W. Goupil, Hassan Chaouk, Troy Holland, Bruktawit T. Asfaw, Stephen D. Goodrich, Lucas Latini
Abstract: Provided are improved agricultural processes for the improved cultivation of rice wherein the crops are treated to control undesired vegetative growth using a plant treatment composition comprising both halosulfuron and thifensulfuron to provide improved herbicidal efficacy against Heteranthera limosa, commonly referred to as “duck salad”. Also provided are compositions useful in the improved agricultural processes, as well as herbicidal treatment regimens. Unexpectedly high rates of efficacy against Heteranthera limosa, amongst rice plant in rice crops are disclosed.
Type:
Grant
Filed:
April 28, 2016
Date of Patent:
November 20, 2018
Assignee:
Canyon Group LLC
Inventors:
Eric Paige Webster, Dominic Frank Alonso, Sergio Comparini, Wallace Keith Majure, Sandra Alcaraz, Charles Paul Grasso, Eric James McEwen, Tak Wai Cheung
Abstract: A method of preparing genipin-rich materials from the fruit of Genipa americana fruit for their use as a cross-linking agent and as a raw material to produce colors is disclosed. The genipin-rich materials can be used in a broad range of applications including personal care, cosmetics, dietary supplements, packaging, textiles, beverages, foodstuffs, drugs, and animal feeds.
Abstract: The present invention relates to the field of Streptococcus. More specifically, the present invention relates to the identification of polypeptides and polynucleotide sequences encoding the same which are involved in the pathogenic mechanism of S. suis. The present invention also relates to the use of such polypeptides in compositions and methods for the prevention, the treatment and diagnosis of S. suis-associated diseases and infections caused by S. suis.